Sort   by:  
 Page size 
UnknownEffectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis.

Aim

To evaluates the effectiveness and safety of the first generation, NS3/4A protease inhibitors (PIs) in clinical practice against chronic C virus, especially in patients with advanced fibrosis.

Methods

Prospective study and non-experimental analysis of a multicentre cohort of 38 Sp...
S-EPMC4533049 | biostudies-literature
GenomicsGenome-Wide Association Study in Systemic Sclerosis

The Scleroderma Family Registry and DNA Repository (Registry) was initially developed as a registry and bio-specimen repository of patients with systemic sclerosis (scleroderma), family members and unaffected normal controls. A case-control design was later adopted due to the lack of avai...

phs000357.v1.p1 | EGA
UnknownIncidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study.
(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. ...
S-EPMC8268420 | biostudies-literature
UnknownEffect of Direct Transportation to Thrombectomy-Capable Center vs Local Stroke Center on Neurological Outcomes in Patients With Suspected Large-Vessel Occlusion Stroke in Nonurban Areas: The RACECAT Randomized Clinical Trial.

Importance

In nonurban areas with limited access to thrombectomy-capable centers, optimal prehospital transport strategies in patients with suspected large-vessel occlusion stroke are unknown.

Objective

To determine whether, in nonurban areas, direct transport to a thrombectomy-capabl...
S-EPMC9073661 | biostudies-literature
UnknownRepurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.

Background

World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs - remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a - in patients hospitalized with coronavirus disease 2019 (Covid-19).

Methods

We randomly assigned inpa...
S-EPMC7727327 | biostudies-literature
Sort   by:  
 Page size